Navigation Links
Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
Date:1/30/2009

Company will have 180 days of marketing exclusivity on the 500 mg strength

PITTSBURGH, Jan. 30 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Divalproex Sodium Extended-release (Divalproex ER) Tablets, 250 mg and 500 mg.

Mylan has been awarded 180 days of marketing exclusivity for the 500 mg strength, which it will begin to ship Feb. 2. Mylan was the first company to file a substantially complete ANDA containing a Paragraph IV certification for the 500 mg strength. Mylan is shipping the 250 mg strength immediately.

Divalproex ER Tablets are the generic version of Abbott Laboratories' Depakote(R) ER and had U.S. sales of approximately $901 million for the 12 months ending Sept. 30, 2008, with $789 million for the 500 mg strength and $112 million for the 250 mg strength.

Currently, Mylan has 119 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
3. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
4. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
5. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
7. Mylan Announces Move to NASDAQ Stock Market
8. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
9. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
10. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... Marshall as a free introduction to SurvivalLife.com along with a ... has caught the attention of Shane Michaels, prompting an investigative ... the most well-known people in the survival and preparation niche, ... with all of the great classes and survival products that ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... September 30, 2014 Hospice & ... annual “In Celebration” gala, honoring three outstanding individuals ... of striving to provide extraordinary and dignified comfort, ... a serious or life-limiting illness. , The event ... Rye, NY and recognized William (Bill) J. McGuinness, ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
Breaking Medicine News(10 mins):Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2
... have covered one-third of the country's children in a ... than 11 million children in 1,301 counties of central ... hepatitis B, said Jiang Zuojun, the Vice-Minister for Health. ... their pace to reach the remaining two-thirds by the ...
... incidence of breast cancer at Brisbane's ABC headquarters at Toowong ... ,ABC managing director Mark Scott said that Dr Joanne Aitken ... by Dr Bruce Armstrong. ,Mr Scott added that ... alongside the panel. ,The review panel was established ...
... The British government's drug watchdog has warned yesterday that the doctors ... bipolar disorder in spite of it being one of the most ... are waiting on an average for eight years to be accurately ... almost 20 years of ill health, of which they might not ...
... poll that was conducted by the nursing union of the ... and harassment a continuing problem in// healthcare. ,Stating ... have suffered abuse from fellow staff and managers over the ... those bullied had wanted changes in their work so as ...
... Industry (ABPI) and the BioIndustry Association (BIA) recommended new ... with extreme care and caution while testing pioneering drugs. ... March left six volunteers in the state of coma. ... The new drug was tested at the Parexel trial ...
... studies shows that alternative and complementary therapies may have ... menopause.// The review article is published in the July ... the JAMA/Archives journals. ,Twenty-five million women will ... of them will experience hot flashes, night sweats, vaginal ...
Cached Medicine News:Health News:Breast Cancer Review Panel Adds Two Experts 2Health News:Bipolar Disorder Not Being Accurately Diagnosed By Doctors In UK 2Health News:Alternative Therapies May Not Ease Menopause Symptoms 2
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
... DIEGO, Aug. 28 Vical Incorporated,(Nasdaq: VICL ... subject in its,Phase 1 trial of the company,s ... placebo-controlled trial will,evaluate safety, tolerability and immune responses ... 45 at two U.S. clinical sites. "We ...
... such ... infectious-disease outbreaks, SEATTLE, Aug. 28 In ... Fred,Hutchinson Cancer Research Center confirm that the avian influenza A ... within a family in,Indonesia. The findings, by biostatistician Ira M. ...
Cached Medicine Technology:Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 2Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 3Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 4Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 2Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 3Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: